Herceptin Given Prior To Surgery Improves The Chance Of Survival Without Relapse For Women With HER2-positive Breast Cancer

News — By on December 13, 2008 at 2:00 am

Standard one year Herceptin treatment provides long-term benefit to patients with high risk of recurrence About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surgery, compared to only around 50% of patients receiving pre-operative chemotherapy alone.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback